Helomics™ to Present at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York

Helomics to Present an Overview of its Personalized Comprehensive Tumor Profiling Platforms

PITTSBURGH--()--Helomics™ Corporation, a privately-held comprehensive personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services, announced today that the Company is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference taking place in New York City at the Millennium Broadway Hotel on March 20, 2015.

Neil J. Campbell, President and Chief Executive Officer of Helomics, will provide an overview of the personalized healthcare landscape, the Company’s business and its comprehensive tumor profiling technologies, including ChemoFx®, during his live presentation and will be available to participate in one-on-one meetings.

Event: BioCentury Future Leaders in the Biotech Industry Conference

Date: Friday, March 20, 2015

Time: 10:30am to 11:00am

Location: Millennium Broadway Hotel, West 44th Street, New York City

Presentation Room: 302/303

Breakout Room: 301

The presentation will be webcast live. To access the webcast, please visit the following link: https://www.webcaster4.com/Webcast/Page/818/7727. The webcast will be archived and available for one year following the live presentation.

About the BioCentury Future Leaders in the Biotech Industry Conference

Future Leaders connects leading portfolio managers, bankers and analysts with investor-validated, milestone-rich private and public companies in key therapeutic areas, offering new investment and partnering opportunities and the chance to find companies with tier-jumping potential. Future Leaders provides the industry's best venue — in a single day — to identify solid investment and partnering prospects. Wall Street and pharma executives will have the opportunity to assess private and public companies with healthy financial profiles, poised to deliver on milestones that could lead to the next tier of valuations. Last year's Future Leaders audience controlled more than $650 billion in equity assets. For more information please visit: http://www.biocentury.com/conferences/futureleaders/dates.

About Helomics™ Corporation

Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com